Promius Pharma, LLC, has acquired the rights to market and distribute Trianex^® 0.05% (Triamcinolone Acetonide Ointment, USP) in the United States from CMP Pharma, Inc. Trianex Ointment, a mid-potency corticosteroid, is notable for its white formulation that has the look and feel of a cream.

“We are pleased to add Trianex into the Promius Pharma family of topical corticosteroid products, which already features Cloderm^® (clocortolone pivalate) Cream, 0.1% and its authorized generic. The portfolio addition of Trianex offers an effective treatment option for chronic, widespread dermatoses, with an excellent safety profile,” said Eric Shenloogian, Associate Director – Marketing for Promius Pharma.

Trianex Ointment will be available in a 430 gram jar and features a proprietary cream-like formulation. It will be the only ointment to offer this combination, making it an appealing option for those patients with inflammatory skin conditions that cover large areas and who don’t like the typical greasy feel of ointments.

“The look and feel of the white ointment and size are significant,” explained Shenloogian, “because patients tell us they would rather not use greasy ointments, especially when they have a large area to cover.  By offering a large (430 gram) jar, instead of a typical small tube, we provide a convenient option for patients to use Trianex.” 

Also, to make it more affordable, Trianex Ointment offers a significant savings program to all eligible insured patients who receive a prescription for the 430 gram jar.*

With Trianex Ointment and Cloderm Cream, Promius Pharma now offers options to cover a wide range of patients with inflammatory skin conditions.